WO2004037278A3 - Dyslokalisationsmoleküle und deren verwendung - Google Patents

Dyslokalisationsmoleküle und deren verwendung Download PDF

Info

Publication number
WO2004037278A3
WO2004037278A3 PCT/EP2003/011525 EP0311525W WO2004037278A3 WO 2004037278 A3 WO2004037278 A3 WO 2004037278A3 EP 0311525 W EP0311525 W EP 0311525W WO 2004037278 A3 WO2004037278 A3 WO 2004037278A3
Authority
WO
WIPO (PCT)
Prior art keywords
delocalization
molecules
medicaments
production
methods
Prior art date
Application number
PCT/EP2003/011525
Other languages
English (en)
French (fr)
Other versions
WO2004037278A2 (de
Inventor
Wolfgang Berdel
Carsten Mueller-Tidow
Hubert Serve
Bjoern Steffen
Original Assignee
Wolfgang Berdel
Carsten Mueller-Tidow
Hubert Serve
Bjoern Steffen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wolfgang Berdel, Carsten Mueller-Tidow, Hubert Serve, Bjoern Steffen filed Critical Wolfgang Berdel
Priority to JP2004545874A priority Critical patent/JP4445867B2/ja
Priority to AU2003283277A priority patent/AU2003283277B2/en
Priority to US10/531,415 priority patent/US8362205B2/en
Priority to EP03775198A priority patent/EP1556070A2/de
Publication of WO2004037278A2 publication Critical patent/WO2004037278A2/de
Publication of WO2004037278A3 publication Critical patent/WO2004037278A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)

Abstract

Die vorliegende Erfindung betrifft Dyslokalisationsmoleküle, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel, insbesondere zur Behandlung von Tumoren.
PCT/EP2003/011525 2002-10-18 2003-10-17 Dyslokalisationsmoleküle und deren verwendung WO2004037278A2 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2004545874A JP4445867B2 (ja) 2002-10-18 2003-10-17 異常局在化分子およびその使用
AU2003283277A AU2003283277B2 (en) 2002-10-18 2003-10-17 Delocalization molecules and use thereof
US10/531,415 US8362205B2 (en) 2002-10-18 2003-10-17 Delocalization molecules and use thereof
EP03775198A EP1556070A2 (de) 2002-10-18 2003-10-17 Dyslokalisationsmolek le und deren verwendung

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10248751.0 2002-10-18
DE10248751A DE10248751A1 (de) 2002-10-18 2002-10-18 Dyslokalisationsmoleküle und deren Verwendung

Publications (2)

Publication Number Publication Date
WO2004037278A2 WO2004037278A2 (de) 2004-05-06
WO2004037278A3 true WO2004037278A3 (de) 2004-09-10

Family

ID=32087027

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/011525 WO2004037278A2 (de) 2002-10-18 2003-10-17 Dyslokalisationsmoleküle und deren verwendung

Country Status (7)

Country Link
US (1) US8362205B2 (de)
EP (1) EP1556070A2 (de)
JP (1) JP4445867B2 (de)
CN (1) CN1729008A (de)
AU (1) AU2003283277B2 (de)
DE (1) DE10248751A1 (de)
WO (1) WO2004037278A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007003216A1 (en) * 2005-07-06 2007-01-11 Universidad Autónoma de Madrid Anti-ccr7 receptor antibodies for the treatment of cancer
US9435809B2 (en) * 2011-07-14 2016-09-06 Memorial Sloan-Kettering Cancer Center Method of treating and reducing the risk of acute myelogenous leukemia
EP2846807B1 (de) 2012-05-09 2023-06-07 The Hong Kong University of Science and Technology Verfahren und verbindungen zur hemmung des mcm-komplexes und deren anwendung bei der behandlung von krebs

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0007217D0 (en) * 2000-03-24 2000-05-17 Europ I Of Oncology Materials and methods relating to the treatment of leukaemias
US7238525B2 (en) * 2000-06-30 2007-07-03 The Regents Of The University Of California Strategy for leukemia therapy
US7229960B2 (en) * 2000-11-03 2007-06-12 University Of Vermont And State Agricultural College Methods and compositions for inhibiting GRB7
US20060019256A1 (en) * 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
LINGGI BRYAN ET AL: "The t(8;21) fusion protein, AML1-ETO, specifically represses the transcription of the p14ARF tumor suppressor in acute myeloid leukemia", NATURE MEDICINE, vol. 8, no. 7, July 2002 (2002-07-01), pages 743 - 750, XP002286638, ISSN: 1078-8956 *
MAO SHIFENG ET AL: "Functional and physical interactions between AML1 proteins and an ETS protein, MEF: Implications for the pathogenesis of t(8;21)-positive leukemias", MOLECULAR AND CELLULAR BIOLOGY, vol. 19, no. 5, May 1999 (1999-05-01), pages 3635 - 3644, XP002286639, ISSN: 0270-7306 *
MÜLLER-TIDOW CARSTEN ET AL: "Redirection of oncoproteins to kill cancer cells.", CELL CYCLE (GEORGETOWN, TEX.) 2003 NOV-DEC, vol. 2, no. 6, November 2003 (2003-11-01), pages 531 - 533, XP001193345, ISSN: 1538-4101 *
See also references of EP1556070A2 *
STEFFEN BJOERN ET AL: "Specific protein redirection as a transcriptional therapy approach for t(8;21) leukemia.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 100, no. 14, 8 July 2003 (2003-07-08), pages 8448 - 8453, XP002286637, ISSN: 0027-8424 *
VIGNERI P ET AL: "INDUCTION OF APOPTOSIS IN CHRONIC MYELOGENOUS LEUKEMIA CELLS THROUGH NUCLEAR ENTRAPMENT OF BCR-ABL TYROSINE KINASE", NATURE MEDICINE, NATURE AMERICA, NEW YORK, US, vol. 7, no. 2, February 2001 (2001-02-01), pages 228 - 234, XP002949103, ISSN: 1078-8956 *
WANG JIANXIANG ET AL: "ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 95, no. 18, 1 September 1998 (1998-09-01), pages 10860 - 10865, XP002286640, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
WO2004037278A2 (de) 2004-05-06
CN1729008A (zh) 2006-02-01
JP2006514545A (ja) 2006-05-11
US20060166876A1 (en) 2006-07-27
AU2003283277B2 (en) 2010-03-04
DE10248751A1 (de) 2004-05-06
EP1556070A2 (de) 2005-07-27
AU2003283277A1 (en) 2004-05-13
US8362205B2 (en) 2013-01-29
JP4445867B2 (ja) 2010-04-07

Similar Documents

Publication Publication Date Title
EG25011A (en) Amino-piperidin-1-yl-xanthines, the production thereof and the use of the same as medicaments.
AU2003293757A1 (en) Novel substituted imidazo-pyridinones and imidazo-pyridazeiones, the production and use thereof as medicaments
IL173204A0 (en) Novel cyanopyrrolidides, methods for the production thereof, and use of the same as medicaments
AU2003282094A1 (en) Novel dihydroxy-methylphenyl derivatives, method for the production and use thereof as medicaments
MX2007002470A (es) Fenilaminotiazoles sustituidos y su uso.
AU2003257465A1 (en) Substituted diaryl heterocycles, method for the production and use thereof as medicaments
HUP0401293A3 (en) Novel dihydropteridinones, method for producing the same and the use thereof as medicaments
HK1085489A1 (en) Chitosan-containing polyaccharide, process for producing the same and use thereof
PL378065A1 (pl) Podstawione związki N-aryloheterocykliczne, sposób ich wytwarzania oraz ich zastosowanie jako środków leczniczych
PL375344A1 (en) Novel carboxamide compounds having an mch-antagonistic effect, medicaments containing said compounds, and methods for the production thereof
IL181012A0 (en) Substituted 8-aminoalkoxi-xanthines, method for the production thereof and use thereof as medicaments
AU2003284596A1 (en) Imidazole derivative, process for producing the same, and use
WO2004050707A3 (de) Tumorspezifische erkennungsmoleküle
HK1081965A1 (en) Pyridopyrimidinone compounds, method for production thereof and medicaments comprising the same
IL162316A0 (en) Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof, the use thereof as medicaments, in addition t
WO2005085188A3 (en) Compounds and methods for anti-tumor therapy
AU2003254864A1 (en) Novel triarylamine polymer, process for producing the same, and use thereof
WO2005089294A3 (en) Synthesis of indenoisoquinoliniums and methods of use
AU2003288023A1 (en) Process for the manufacture of 1,2-epoxy-3-chloropropane
WO2002010152A3 (de) Neue indolderivate und deren verwendung als arzneimittel
TW200517144A (en) Flavouring-containing pharmaceutical formulations with improved pharmaceutical properties
PL371784A1 (en) Pentafluorosulfanyl-benzoylguanidine, method for the production thereof and its utilization as medicament or diagnostic agent and medicament containing same
WO2001049654A3 (de) Substituierte aminomethyl-phenyl-cyclohexanderivate
ZA200601001B (en) Substituted thienoimidazoles, method for production and use thereof as medicament or diagnostic and medicament comprising the same
MXPA03006648A (es) Compuestos antitombroticos, su preparacion y su utilizacion como medicamentos.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004545874

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003283277

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003775198

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 20038A70533

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003775198

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006166876

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10531415

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10531415

Country of ref document: US